Lansoprazole (1ansoprazole) is a new generation of benzimidazole proton pump inhibitors omeprazole. After lansoprazole is mainly through the H + inhibition of gastric parietal cells, K + -ATP activity, thereby strong and long-lasting inhibition of acid secretion. Because of its unique mechanism, high specificity, strong inhibition, long time and can be widely used for the treatment of acid secretion and digestive function disorder related diseases. At present is mainly used for the treatment of acid related diseases and eradication of Helicobacter pylori
The treatment, such as gastric and duodenal ulcer. But because of lansoprazole on wet, light, heat sensitive, exposure to air and perishable, water solubility, easy degradation in acidic conditions for preparation and storage of inconvenience.
Recent studies have found that betacyclodextrin and hydroxypropyl betacyclodextrin inclusion can be with lansoprazole. Betacyclodextrin and hydroxypropyl betacyclodextrin times compared, sulfobutyl ether beta cyclodextrin (SBE- beta -CD) has better security (renal toxicity and hemolysis, stronger solubilization and small) inclusion ability and better stability. Sulfobutyl ether beta cyclodextrin inclusion compound can greatly enhance lansoprazole in water solubility and dissolution rate.
Specializing in the production of cyclodextrins in Shandong Binzhou Zhiyuan Bio Technology Co. Ltd. and its derivatives, the main products of hydroxypropyl betacyclodextrin and sulfobutyl ether beta cyclodextrin sodium. The sulfobutyl ether beta cyclodextrin sodium products have been obtained by the State Food and Drug Administration: drug registration acceptance notice, acceptance number: CXFS1500004 Lu at the same time, and received clinical approval; by the U.S. Food and Drug Administration DMF for the record, the record number: 30167